- Tytuł:
- RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma
- Autorzy:
- Źródło:
-
Annals of Hematology . 102(7):1773-1787
Czasopismo naukowe